News Jazz pays $145m to resolve Xyrem antitrust disputes Jazz Pharma has offered to pay $145m to settle claims it paid to prevent generic versions of its narcolepsy drug Xyrem from reaching the US market.
News Pharma tariffs "will hurt US consumers most of all" If pharmaceuticals are included in President Trump's 'Liberation Day' tariffs, it is US consumers who will suffer the most, says a new report.
News FDA approves first generics of anticoagulant Xarelto The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto.
News Trump tariffs 'would strain the pharma supply chain' Pharma organisations in the US have said that Trump's tariffs plan could drive up the cost of generics, block supply chains and worsen drug shortages.
R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
News Novartis bid to block generic Entresto in US suffers setback An appeals court in the US has declined to overturn an attempt by Novartis to block the launch of a generic of its heart failure blockbuster Entresto.
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.